47 Supported by research
Roughly 45% to half of the United States population has inadequate dietary magnesium intake.
"Nearly half of the population in the United States doesn't get enough magnesium, primarily because our diets lack sufficient dark leafy greens, where magnesium is abundantly found, hidden within the chlorophyll that gives plants their vibrant green color." (said at 0:02:03)
Nationally representative dietary data from the National Health and Nutrition Examination Survey (NHANES) consistently show that roughly 45% to 48% of the United States population fails to meet the Estimated Average Requirement (EAR) for magnesium, even when accounting for fortified foods and dietary supplements. When considering dietary intake from food alone, the proportion below the EAR exceeds 50%.
- supports: Foods, fortificants, and supplements: Where do Americans get their nutrients? (The Journal of nutrition 2011) · cited 474x in the literature
"However, more of the population had total usual intakes below the EAR for vitamins A, C, D, and E (34, 25, 70, and 60%, respectively), calcium (38%), and magnesium (45%)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Multivitamin/mineral supplement contribution to micronutrient intakes in the United States… (Journal of the American College of Nutrition 2014) · cited 132x in the literature
"Large portions of the population had total usual intakes (food and MVMM supplement use) below the estimated average requirement for vitamins A (35%), C (31%), D (74%), and E (67%) as well as calcium (39%) and magnesium (46%)." (abstract, results, passage verified)
pubmedfull study (doi)
Magnesium threonate contains a very low amount of elemental magnesium.
"and that is because magnesium threonate contains a very low amount of elemental magnesium." (said at 0:00:35)
Magnesium L-threonate, [Mg(C4H7O5)2], has a molecular mass consisting predominantly of the two threonate chelating molecules (~135 g/mol each) relative to a single magnesium ion (~24.3 g/mol). Consequently, elemental magnesium makes up only approximately 7% to 8.3% of magnesium L-threonate by weight (depending on hydration). Standard clinical and supplemental doses of 1,500 to 2,000 mg of magnesium L-threonate typically yield only about 100 to 145 mg of elemental magnesium, representing one of the lowest elemental percentages among common magnesium dietary supplement forms (compared to ~60% in magnesium oxide or ~14% in magnesium bisglycinate).
Insufficient magnesium levels are linked to accelerated brain volume loss and earlier onset of dementia.
"More alarmingly, recent studies indicate a potential link between insufficient magnesium levels and accelerated brain volume loss, which could hasten the onset of dementia as we age." (said at 0:01:38)
Observational cohort studies support an association between lower dietary or serum magnesium and smaller brain volumes / neurodegenerative markers. In an analysis of 6,001 UK Biobank participants (Alateeq et al., 2023), lower dietary magnesium intake trajectories were associated with smaller gray matter, white matter, and hippocampal volumes, as well as increased white matter lesion volume. Similarly, in the Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS, n=1,466), lower serum magnesium was associated with significantly lower brain lobe volumes and higher odds of subclinical cerebrovascular disease. Because these findings are observational and cross-sectional, they establish a potential link rather than direct causal acceleration of dementia, which aligns with the speaker's cautious framing.
- supports: Associations of Serum Magnesium with Brain Morphology and Subclinical Cerebrovascular Dise… (Nutrients 2021) · cited 11x in the literature
"After adjusting for demographics, biomarkers, medications, and cardiometabolic risk factors, higher circulating magnesium was associated with greater total brain volume and frontal, temporal, and parietal lobe volumes (volumes 0.14 to 0.19 standard deviations higher comparing Q5 to Q1)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Dietary magnesium intake is related to larger brain volumes and lower white matter lesions… (European journal of nutrition 2023) · cited 21x in the literature
"On average, higher baseline dietary Mg intake was associated with larger brain volumes (gray matter [GM]: 0.001% [SE = 0.0003]; left hippocampus [LHC]: 0.0013% [SE = 0.0006]; and right hippocampus [RHC]: 0.0023% [SE = 0.0006]) in both men and women... the "low-increasing" trajectory was associated with smaller brain volumes (GM: - 1.67%, [SE = 0.30]; white matter [WM]: - 0.85% [SE = 0.42]; LHC: - 2.43% [SE = 0.59]; and RHC: - 1.50% [SE = 0.57]) and larger WMLs (1.6% [SE = 0.53])." (abstract, results, passage verified)
pubmedfull study (doi)
Magnesium acts as a cofactor for about 300 different enzymes in the human body.
"Magnesium is a cofactor for about 300 different enzymes in our bodies, which are special proteins that perform functions. Magnesium is required for these enzymes to work properly." (said at 0:02:33)
The claim accurately reflects established human biochemistry. Magnesium is a vital mineral that serves as an essential cofactor for over 300 enzymatic reactions in the human body, particularly those involving ATP utilization, nucleic acid synthesis, and carbohydrate and lipid metabolism.
Athletes and heavy sauna users require approximately 10% to 20% more magnesium than the RDA due to losses in sweat and urine.
"And athletes and those that have high physical activity, including people that are also regular sauna users, may need additionally about 10 to 20% above the Recommended Dietary Allowance due to their greater magnesium loss through urine and sweat." (said at 0:03:24)
Scientific reviews and metabolic studies evaluating magnesium dynamics during physical exercise and heat exposure indicate that strenuous physical activity increases magnesium excretion through sweat and urine, potentially raising daily requirements by approximately 10% to 20% above standard dietary recommendations. Physiological studies evaluating sauna use and heat exposure similarly demonstrate elevated magnesium losses via sweat and urine.
NHANES nutritional survey data shows average daily magnesium intake in the US is around 230 mg for women and 320 mg for men.
"There's data from nutritional surveys like NHANES revealing that the average intake of magnesium in the US falls below the RDA, so the typical intake for women is around 230 milligrams per day while men consume about 320 milligrams per day." (said at 0:03:46)
Nutritional survey data from the National Health and Nutrition Examination Survey (NHANES) and USDA dietary surveys consistently show that average dietary magnesium intake in the United States falls below the Recommended Dietary Allowance (RDA; 310–320 mg/day for adult women and 400–420 mg/day for adult men). Across several NHANES cycles, average dietary magnesium intake (from food alone) is approximately 230–260 mg/day for women and 320–350 mg/day for men, with a substantial portion of the population failing to meet either the Estimated Average Requirement (EAR) or RDA.
- supports: Trends in Reported Calcium and Magnesium Intake from Diet and Supplements by Demographic F… (Journal of the Academy of Nutrition and Dietetics 2024) · cited 5x in the literature
"Magnesium intake reported from diet was lowest in adults ages 71 years and older (276 mg), whereas total magnesium intake and proportion of meeting the EAR from both diet and supplements was lowest in women (302 mg) and men (52%), respectively" (abstract, results, passage verified)
pubmedfull study (doi) - supports: Global Dietary Magnesium Deficiency: Prevalence, Underlying Causes, Health Consequences, a… (International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition 2025) · cited 1x in the literature
"The recommended dietary allowance (RDA) for adults in the United States is approximately 420 mg/day for men and 320 mg/day for women, yet large proportions of the population fail to meet these levels with national nutrition surveys consistently documenting inadequate intake." (abstract, results, passage verified)
pubmedfull study (doi)
Net dietary magnesium absorption is only about 50% on average.
"The net absorption of magnesium in the diet is only about 50%." (said at 0:05:08)
Human nutritional balance and absorption studies establish that fractional/net intestinal absorption of dietary magnesium typically ranges between 30% and 50% under standard physiological intakes. Fractional absorption varies inversely with the amount ingested (dose-dependent absorption) and depends on the chemical matrix and magnesium status, making ~50% an accurate upper-to-average estimate for typical dietary intakes.
Supplemental zinc at doses higher than 142 mg per day limits the bioavailability and absorption of magnesium.
"The other really important factor that can limit the bioavailability of magnesium is excessive supplemental zinc at doses higher than 142 milligrams a day, which is quite high." (said at 0:06:40)
The claim directly reflects findings from a human metabolic balance trial by Spencer et al. (1994). In adult males across varying calcium intake levels, high-dose zinc supplementation of 142 mg/day (given as zinc sulfate) significantly decreased intestinal magnesium absorption and reduced overall magnesium balance.
Short-term high-dose zinc supplementation of about 80 mg per day lessens respiratory illness symptoms and shortens disease duration.
"So the exception of people doing a little bit of a mega sort of a higher dose of zinc would be during illness or the onset of illness, where higher zinc dose supplementation, like on the order of, for example, 80 milligrams a day, has been shown to lessen respiratory illness symptoms and decrease duration of illness as well." (said at 0:07:07)
Meta-analyses of randomized, placebo-controlled trials demonstrate that short-term administration of zinc (primarily as zinc acetate or zinc gluconate lozenges initiated at the onset of illness) at doses around 80 to 92 mg/day significantly reduces both the duration of common cold illness and the duration of specific respiratory symptoms (such as cough, nasal discharge, nasal congestion, and hoarseness) by roughly 30% to 45%, whereas doses below 75 mg/day generally show no significant benefit.
- supports: The effectiveness of high dose zinc acetate lozenges on various common cold symptoms: a me… (BMC family practice 2015) · cited 49x in the literature
"We analyzed three randomized trials on zinc acetate lozenges for the common cold administering zinc in doses of 80-92 mg/day... Zinc acetate lozenges shortened the duration of nasal discharge by 34% (95% CI: 17% to 51%), nasal congestion by 37% (15% to 58%), sneezing by 22% (-1% to 45%), scratchy throat by 33% (8% to 59%), sore throat by 18% (-10% to 46%), hoarseness by 43% (3% to 83%), and cough by 46% (28% to 64%)." (abstract, results)
pubmedfull study (doi) - supports: Zinc lozenges and the common cold: a meta-analysis comparing zinc acetate and zinc glucona… (JRSM open 2017) · cited 126x in the literature
"Five trials used zinc doses of 80-92 mg/day, common cold duration was reduced by 33%, and two trials used zinc doses of 192-207 mg/day and found an effect of 35%." (abstract, results, passage verified)
pubmedfull study (doi)
In the human body, approximately 60% of magnesium is in the skeleton, 27% in muscle, 6-7% in other cells, and less than 1% in extracellular fluid.
"Roughly 60% of all the magnesium is found in the skeleton, so most of our magnesium is found in our bones. About 27% is found in the muscle, and 6 to 7% is found in other cells. Less than 1% is found outside of our cells." (said at 0:09:16)
The speaker's description of magnesium distribution across the human body accurately reflects standard human physiology. The vast majority of total body magnesium is stored in bone (approximately 50% to 60%) and skeletal muscle (roughly 20% to 27%), with the remainder in other soft tissue cells, while less than 1% resides in the extracellular fluid and serum.
The body regulates plasma magnesium concentrations tightly within the range of approximately 0.7 to 1.0 mmol/L.
"The body regulates plasma magnesium concentrations within a very narrow range, so typically around 0.7 to 1 millimolar per liter." (said at 0:09:58)
Established physiological literature confirms that circulating (serum/plasma) magnesium concentrations are tightly regulated by intestinal absorption and renal excretion within a narrow normal reference range of approximately 0.7 to 1.0–1.1 mmol/L. Concentrations below 0.7 mmol/L are clinically classified as hypomagnesemia.
The Institute of Medicine set the upper tolerable limit for daily supplemental magnesium at 350 mg per day.
"The US Institute of Medicine's Food and Nutrition Board has set the upper safe limit for daily supplemental magnesium intake at 350 milligrams per day." (said at 0:12:12)
The statement accurately reflects the dietary reference guidelines established by the US Institute of Medicine (IOM) Food and Nutrition Board. The IOM established a Tolerable Upper Intake Level (UL) of 350 mg per day for magnesium derived specifically from supplemental or pharmacological sources in adults, with mild diarrhea identified as the critical adverse effect.
In humans, an increase of up to 300% in blood magnesium results in less than a 19% change in cerebrospinal fluid magnesium content.
"So in humans, it's been found that even an increase up to 300% in blood magnesium results in less than 19% change in the cerebrospinal fluid magnesium content." (said at 0:15:50)
Human clinical investigations and physiological reviews confirm that cerebrospinal fluid (CSF) magnesium levels are tightly regulated across the blood-brain barrier by active transport mechanisms. Consequently, large increases in peripheral serum magnesium (induced hypermagnesemia, such as during high-dose intravenous magnesium sulfate therapy) produce only minor elevations in CSF magnesium concentration, typically in the range of 11% to 18% (less than 19%).
In mouse models, magnesium threonate at a human equivalent dose of 8.1 mg/kg body weight improves cognition and reduces amyloid-beta plaques.
"So some animal evidence suggests that magnesium threonate can easily get across the blood-brain barrier, and at a human equivalent dose of 8.1 milligrams per kilogram body weight—so that would be around 662 milligrams for a 180-pound person—can improve cognition and decrease amyloid-beta plaques." (said at 0:16:14)
Preclinical studies in transgenic mouse models of Alzheimer's disease (such as APPswe/PS1dE9 mice) demonstrate that treatment with magnesium-L-threonate elevates brain magnesium levels, enhances synaptic plasticity, decreases amyloid-beta plaque burden, and ameliorates cognitive deficits. Because this evidence is currently limited to animal and in vitro models, the certainty of evidence for clinical translation to humans remains very low.
Whyte et al. demonstrated that adrenaline infusion immediately lowers magnesium levels in humans, and levels remain significantly reduced one hour post-infusion.
"there was a study by Whyte et al. that looked at how adrenaline, which is a well-known stress hormone, affects our magnesium levels. And what they found I personally thought was an interesting study: they found when adrenaline was infused into people, it didn't just temporarily lower magnesium levels; these levels stayed significantly reduced even an hour after stopping the adrenaline infusion, without showing any immediate signs of bouncing back." (said at 0:23:52)
A placebo-controlled trial by Whyte et al. (1987) evaluated the effects of adrenaline infusions in eight healthy subjects. The authors demonstrated that plasma magnesium concentrations decreased significantly during adrenaline infusion and failed to recover during a one-hour observation period following the cessation of the infusion.
Meta-analyses of randomized controlled trials show magnesium supplementation improves subjective sleep metrics, including PSQI scores, sleep efficiency, and duration.
"A meta-analysis of some trials suggests that magnesium supplementation can improve some sleep metrics, including scores on the Pittsburgh Sleep Quality Index, and also can improve sleep efficiency and duration." (said at 0:29:58)
Published systematic reviews and meta-analyses of randomized controlled trials (RCTs) evaluating magnesium supplementation for insomnia/sleep quality have reported improvements across several subjective and objective metrics, including sleep onset latency, Pittsburgh Sleep Quality Index (PSQI) scores, sleep efficiency, and total sleep duration. However, the existing body of evidence is limited by small sample sizes across included trials, methodological heterogeneity, and moderate-to-high risk of bias, resulting in low overall certainty.
Threonic acid is a metabolite of vitamin C.
"So this form of magnesium is chelated to threonic acid, and that is a metabolite of vitamin C." (said at 0:16:40)
Threonic acid (threonate) is a well-characterized downstream metabolic and breakdown product of ascorbic acid (vitamin C) oxidation.
A 2016 randomized clinical trial in 44 participants found that 1,500 to 2,000 mg/day of magnesium threonate (Magtein) over 12 weeks did not significantly improve individual cognitive tests alone, but reached statistical significance when all four cognitive test scores were pooled.
"The initial study that I think garnered a lot of attention was published in 2016. It was a small-scale study that only had 44 participants total. Those in the treatment group took daily doses of about 1,500 to 2,000 milligrams of magnesium threonate, so this is marketed as Magtein, and they took it for over 12 weeks... there was no significant difference observed when each of these four different measured cognitive tests were looked at in isolation compared to the placebo group. But if the data was all pooled together, so all four cognitive tests were then pooled together, then there was a statistically significant difference in cognitive function compared to the placebo group." (said at 0:17:30)
A 2016 randomized, double-blind, placebo-controlled clinical trial by Liu et al. evaluated 44 older adults (aged 50-70) with cognitive impairment randomized to receive MMFS-01 (magnesium L-threonate / Magtein, 1,500 to 2,000 mg/day, n=23) or placebo (n=21) for 12 weeks. The trial evaluated four cognitive domains and found that overall cognitive ability, measured by a composite pooled score, improved significantly in the treatment group compared to placebo (p = 0.003), precisely matching the speaker's description.
- supports: Efficacy and Safety of MMFS-01, a Synapse Density Enhancer, for Treating Cognitive Impairm… (Journal of Alzheimer's disease : JAD 2016) · cited 59x in the literature
"We conducted a randomized, double-blind, placebo-controlled, parallel-designed trial in older adult subjects (age 50-70) with cognitive impairment. Subjects were treated with MMFS-01 (n = 23) or placebo (n = 21) for 12 weeks and cognitive ability, sleep quality, and emotion were evaluated. Overall cognitive ability was determined by a composite score of tests in four major cognitive domains. With MMFS-01 treatment, overall cognitive ability improved significantly relative to placebo (p = 0.003; Cohen's d = 0.91)." (abstract, methods and results, passage verified)
pubmedfull study (doi)
Approximately 45% of the population has insufficient dietary magnesium intake.
"So we know that 45% of the population has insufficient magnesium intake, okay? So 55% have sufficient levels of magnesium." (said at 0:30:58)
Nationally representative dietary survey data from the United States (National Health and Nutrition Examination Survey, NHANES) show that approximately 45% to 50% of Americans have usual dietary magnesium intakes below the Estimated Average Requirement (EAR). For example, dietary modeling and intake assessments from NHANES 2007–2010 show baseline prevalence of magnesium intake below the EAR among adult age-sex subgroups ranging from approximately 45% to 88% from food sources alone.
- supports: Consuming the daily recommended amounts of dairy products would reduce the prevalence of i… (Nutrition journal 2015) · cited 130x in the literature
"Increasing dairy consumption to recommended amounts would result in a significant reduction in the percent of adults with calcium, magnesium, and vitamin A intakes below the Estimated Average Requirement (EAR) when considering food intake alone (0-2.0 vs. 9.9-91.1%; 17.3-75.0 vs. 44.7-88.5%; 0.1-15.1 vs. 15.3-48.0%, respectively)" (abstract, results, passage verified)
pubmedfull study (doi) - supports: Impact of Frequency of Multi-Vitamin/Multi-Mineral Supplement Intake on Nutritional Adequa… (Nutrients 2017) · cited 99x in the literature
"Except for calcium, magnesium, and vitamin D, most frequent MVMS use (≥21 days/30 days) virtually eliminated inadequacies of the nutrients examined, and was associated with significantly lower odds ratios of deficiency for the examined nutrient biomarkers except for iron." (abstract, results, passage verified)
pubmedfull study (doi)
In a UK Biobank study of over 6,000 participants aged 40 to 73, higher dietary magnesium intake (~550 mg/day vs ~350 mg/day) was associated with larger gray matter and hippocampal volumes, equivalent to approximately one year of reduced brain aging.
"So this was an observational study using data from over 6,000 participants, they were aged 40 to 73, it was the UK Biobank data, and those who reported a higher magnesium intake had, on average, larger brain volumes, which could convey up to approximately one year of reduced brain aging compared to those with lower magnesium intakes. So the results revealed that the higher dietary magnesium consumption—this was about 550 milligrams per day—seemed to correlate with larger gray matter and hippocampal volumes than the average intake of about 350 milligrams per day" (said at 0:34:14)
A 2023 observational study by Alateeq and colleagues analyzed 6,001 participants aged 40 to 73 from the UK Biobank and found that higher dietary magnesium intake was significantly associated with larger total gray matter and hippocampal volumes. Specifically, the authors calculated that an intake of approximately 550 mg/day compared with a normal baseline intake of ~350 mg/day was associated with greater brain volume equivalent to approximately one year of reduced brain aging by age 55, especially in post-menopausal women. Because this is an observational cohort study relying on dietary recall, the GRADE certainty is low due to residual confounding and observational design.
Higher cerebral magnesium levels decrease oxidative stress and inflammation, and improve synaptic plasticity.
"Higher cerebral magnesium levels have been shown to decrease oxidative stress and inflammation and improve synaptic plasticity, also counteract other mechanisms leading to neurodegeneration." (said at 0:35:41)
Preclinical and mechanistic studies demonstrate that elevating cerebral magnesium levels enhances synaptic plasticity (via upregulation of synaptic proteins such as synaptophysin and PSD-95, and signaling molecules like BDNF and CREB), reduces oxidative stress (by boosting endogenous antioxidant defenses such as SOD, catalase, and glutathione), and attenuates neuroinflammation and excitotoxicity. Evidence is primarily derived from animal models and in vitro mechanistic studies evaluating brain-permeable magnesium formulations (such as magnesium L-threonate and magnesium acetyl-taurate).
- supports: Magnesium (Mg 2+ ): Essential Mineral for Neuronal Health: From Cellular Biochemistry to C… (Current pharmaceutical design 2024) · cited 43x in the literature
"Recent studies have highlighted the significance of Mg 2+ in neuroprotection, showing its ability to attenuate oxidative stress, reduce inflammation, and mitigate excitotoxicity, thereby safeguarding neuronal health." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Enhanced Neurophysiological Benefits of Magnesium-Acetyl-Taurate Over Magnesium-L-Threonat… (Neuromolecular medicine 2026) · cited 3x in the literature
"These improvements correlated with increased expression of key proteins, including brain-derived neurotrophic factor (BDNF), cAMP response element-binding protein (CREB), Nrf2, HO-1, cAMP, and synaptic proteins such as synaptophysin and PSD-95, which are crucial for synaptic plasticity and cognition. Additionally, MAT treatment was associated with alteration inantioxidant markers, including superoxide dismutase (SOD), glutathione (GSH), catalase, and coenzyme Q10 (CoQ10), indicating better cellular defense against oxidative stress." (abstract, results, passage verified)
pubmedfull study (doi)
A systematic review showed that individuals with Alzheimer's disease have significantly lower plasma magnesium levels compared to healthy controls.
"So there was a recent systematic review that revealed individuals with Alzheimer's disease also have significantly lower plasma magnesium levels compared to healthy controls." (said at 0:35:51)
A 2021 systematic review and meta-analysis assessing circulating magnesium levels in patients with Alzheimer's disease found that pooled serum and plasma magnesium levels were significantly reduced in individuals with Alzheimer's disease compared to healthy controls (standardized mean difference = -0.89; 95% CI [-1.36, -0.43]; P < 0.001 across 1,112 patients and 1,001 controls). The certainty of this observational evidence is graded as low due to the cross-sectional design of the included case-control studies and substantial heterogeneity.
A 17-year prospective study of over 1,000 middle-aged adults found that those consuming at least 196 mg/day of magnesium had a 37% lower risk of dementia compared to those consuming 174 mg/day or less.
"In a study that followed over 1,000 middle-aged adults for 17 years, researchers found that those who ate the most magnesium—so they were getting at least 196 milligrams per day—had a 37% lower chance of getting dementia when they got older compared to those who ate the least magnesium, so they were getting 174 milligrams per day or less." (said at 0:36:38)
The claim accurately reports the findings from the Hisayama Study (Ozawa et al., 2012), a prospective cohort study that followed 1,081 community-dwelling Japanese adults aged 60 and older for 17 years. The study found that individuals in the highest quartile of dietary magnesium intake had a 37% lower risk of developing all-cause dementia compared to those in the lowest quartile (multivariable-adjusted HR = 0.63, 95% CI: 0.40–1.01), with an even stronger reduction observed specifically for vascular dementia (HR = 0.26, 95% CI: 0.11–0.61). Because this is an observational cohort study relying on self-reported dietary questionnaires, certainty is graded as low.
- supports: Self-reported dietary intake of potassium, calcium, and magnesium and risk of dementia in … (Journal of the American Geriatrics Society 2012) · cited 126x in the literature
"During a 17-year follow-up, 303 participants experienced all-cause dementia... The multivariable-adjusted HRs for the development of all-cause dementia were 0.52 (95% confidence interval [CI] = 0.30-0.91), 0.64 (95% CI = 0.41-1.00), and 0.63 (95% CI = 0.40-1.01) for the highest quartiles of potassium, calcium, and magnesium intake, respectively, compared with the corresponding lowest quartiles." (abstract, results)
pubmedfull study (doi)
An observational study of over 2,500 mentally healthy older adults found that dietary magnesium intake over 407 mg/day was linked to better cognitive function in women.
"And again, another observational study, this was over 2,500 older adults who are mentally healthy, again found higher magnesium intake—this was over 407 milligrams per day—was also linked to overall better brain function, but this benefit was actually only seen in women." (said at 0:37:30)
A cross-sectional observational analysis of 2,508 cognitively assessed older adults (aged ≥60 years) from the National Health and Nutrition Examination Survey (NHANES 2011–2014) evaluated the association between total magnesium intake and cognitive performance. Higher total magnesium intake (specifically comparing the highest quartile to the lowest) was independently associated with a higher global cognitive z-score, with the positive association primarily evident among women, non-Hispanic Whites, and individuals with sufficient serum vitamin D levels.
- supports: Association between magnesium intake and cognition in US older adults: National Health and… (Alzheimer's & dementia (New York, N. Y.) 2022) · cited 33x in the literature
"Based on the National Health and Nutrition Survey (NHANES) between 2011 and 2014, the study included 2508 participants aged 60 years and older. Linear regression models were used to examine the association of total magnesium intake with cognition. After adjusted demographic and other confounding factors, intakes of energy and total calcium, and serum vitamin D level, higher intake of total magnesium was independently associated with 0.15 higher global cognitive z -score (95% confidence interval, 0.02 to 0.28 for highest vs. lowest quartile, P trend = .037). The positive association of total magnesium intake with global cognition was primarily presented among women, non-Hispanic Whites, and those with sufficient serum vitamin D levels (≥50 nmol/L), although interactions were not significant." (abstract, results, passage verified)
pubmedfull study (doi)
Five randomized controlled trials indicate that magnesium supplementation effectively reduces the frequency and intensity of migraine relapses.
"There were five randomized controlled trials that indicate that magnesium supplementation can effectively reduce the frequency and intensity of migraine relapses." (said at 0:41:43)
Multiple randomized controlled trials and subsequent systematic reviews and meta-analyses demonstrate that oral magnesium supplementation is effective for migraine prophylaxis, significantly reducing both the frequency and intensity/severity of migraine attacks.
The effective dose of magnesium for preventing migraines is approximately 600 mg per day.
"The effective magnesium dose for preventing migraines seems to be around 600 milligrams per day, which is almost twice the suggested upper limit." (said at 0:42:10)
Clinical trials and systematic reviews evaluating oral magnesium supplementation for migraine prophylaxis commonly investigate and identify an effective dose of 600 mg per day (often as magnesium citrate/trimagnesium dicitrate). Double-blind randomized controlled trials demonstrate that 600 mg/day significantly reduces migraine attack frequency and migraine days compared to placebo. This dose exceeds the established dietary tolerable upper intake level (UL) for supplemental magnesium (350 mg/day in adults), commonly leading to mild gastrointestinal side effects such as diarrhea.
DNA polymerases require magnesium as a cofactor to replicate DNA during cell division.
"So DNA replication, which is necessary to make a new cell, is really vital for that, you know, process of making a new cell, and magnesium plays a role in DNA replication as well. It's essential for the proper functioning of those enzymes called DNA polymerases." (said at 0:46:46)
DNA polymerases are well-established, canonical two-metal-ion-dependent enzymes that require divalent cations—predominantly magnesium (Mg2+) under physiological conditions—as essential cofactors for the catalysis of DNA synthesis during replication and repair. Mg2+ ions coordinate incoming deoxynucleotide triphosphates (dNTPs) and active-site carboxylate residues, facilitating nucleophilic attack by the 3'-hydroxyl group of the primer strand on the alpha-phosphate of the incoming nucleotide and stabilizing the transition state.
In the VITAL study of over 66,000 individuals aged 50 to 76, magnesium intake of 75% to 99% of the RDA was associated with a 42% increased risk of pancreatic cancer, and intake below 75% was associated with a 76% increased risk.
"So this was part of the Vitamins and Lifestyle study, or the VITAL study. It was from the year 2000 to 2008. Among the 151 participants who ended up developing pancreatic cancer, those with magnesium intake below the RDA had a significantly higher risk of pancreatic cancer. Specifically, those getting 75 to 99% of the RDA, the risk was increased by 42%, and for those with less than 75% of the RDA, that risk jumped to 76%." (said at 0:48:21)
In the prospective VITamins And Lifestyle (VITAL) cohort study of 66,806 participants aged 50–76 years followed between 2000 and 2008, 151 participants developed pancreatic cancer. Compared to individuals who met 100% or more of the Recommended Dietary Allowance (RDA) for magnesium, those consuming 75% to 99% of the RDA had a multivariable-adjusted hazard ratio (HR) of 1.42 (a 42% increase in risk; 95% CI 0.91–2.21), and those consuming less than 75% of the RDA had an HR of 1.76 (a 76% increase in risk; 95% CI 1.04–2.96). Because this is observational data, certainty is rated as low.
In the VITAL study cohort, every 100 mg/day decrease in magnesium intake was associated with a 24% increase in pancreatic cancer incidence.
"But what was even more striking about that study was that for every 100 milligram per day decrease in magnesium intake, there was an increase in a 24% increase in pancreatic cancer incidence. So this was in a dose-dependent manner." (said at 0:48:56)
In a prospective analysis of 66,806 participants in the VITamins And Lifestyle (VITAL) study followed for an average of 6.8 years, multivariable-adjusted Cox regression models found that every 100 mg/day decrement in magnesium intake was associated with a 24% increase in the risk of developing pancreatic cancer (hazard ratio: 1.24; 95% CI: 1.02–1.50; P for trend = 0.03). Because this is an observational cohort study, residual confounding cannot be ruled out.
The Paris Prospective Study 2 of 4,000 men aged 30 to 60 over 18 years found that the highest magnesium levels were associated with 40% lower all-cause mortality and 50% lower cancer mortality compared to the lowest levels.
"There was another study, this was this was the Paris Prospective Study 2, which followed about 4,000 men aged 30 to 60 over 18 years, and that study found that men with the highest magnesium levels, that that was associated with a 40% lower all-cause mortality and a 50% lower decrease in cancer death compared to those with the lowest magnesium levels." (said at 0:50:20)
The Paris Prospective Study 2 followed 4,035 men aged 30 to 60 years over an 18-year period. In Cox proportional hazards models adjusting for confounders, men in the highest quartile of serum magnesium had a 40% reduction in relative risk for all-cause mortality (RR = 0.6; 95% CI: 0.4–0.8) and a 50% reduction in cancer mortality (RR = 0.5; 95% CI: 0.3–0.8) compared to those in the lowest quartile. As an observational cohort study, GRADE certainty is low.
- supports: Zinc, copper, and magnesium and risks for all-cause, cancer, and cardiovascular mortality. (Epidemiology (Cambridge, Mass.) 2006) · cited 271x in the literature
"Data from the Paris Prospective Study 2, a cohort of 4035 men age 30-60 years at baseline, were used to assess the association between serum zinc, copper, and magnesium and all-cause, cancer, and cardiovascular disease mortality... During 18-year follow up, 339 deaths occurred, 176 as a result of cancer and 56 of cardiovascular origin... High magnesium values were negatively related to mortality with a 40% decrease in RR for all-cause (0.6; 0.4-0.8) and cardiovascular deaths (0.6; 0.2-1.2) and by 50% for cancer deaths (0.5; 0.3-0.8)." (abstract, results, passage verified)
pubmedfull study (doi)
A meta-analysis found that each additional 100 mg per day of dietary magnesium was associated with a 6% reduction in all-cause mortality and a 5% reduction in cancer mortality.
"So specifically, for every additional 100 milligrams per day of dietary magnesium, there was a 6% reduction in all-cause mortality and a 5% reduction in cancer mortality. And again, this was in a dose-dependent manner." (said at 0:51:48)
A 2021 systematic review and dose-response meta-analysis of prospective cohort studies (19 publications, 1,168,756 participants) evaluated dietary magnesium intake in relation to mortality. The linear dose-response meta-analysis found that each additional 100 mg/day of dietary magnesium was associated with a 6% reduced risk of all-cause mortality and a 5% reduced risk of cancer mortality. Because these data come from observational prospective cohort studies rather than randomized controlled trials, the overall certainty of evidence for a causal reduction is low.
A meta-analysis of three studies found a non-significant positive association between supplemental magnesium intake and cancer mortality risk.
"The supplemental magnesium intake showed a non-significant positive association with cancer mortality risk based on three studies." (said at 0:52:43)
A systematic review and meta-analysis of prospective cohort studies examining magnesium intake and mortality outcomes (Boushehri et al., 2021) found that supplemental magnesium intake was evaluated for cancer mortality across three studies and demonstrated a non-significant association with cancer mortality risk. The body of evidence comes from observational cohort studies.
- supports: Total, Dietary, and Supplemental Magnesium Intakes and Risk of All-Cause, Cardiovascular, … (Advances in nutrition (Bethesda, Md.) 2021) · cited 68x in the literature
"For supplemental and total magnesium intakes, we did not find any significant associations with risks of all-cause, CVD, and cancer mortality." (abstract, results, passage verified)
pubmedfull study (doi)
A one-year supplementation study found that magnesium supplementation enhanced bone mass in the hips of peripubertal girls.
"There's been a year-long magnesium supplementation study that found that magnesium supplementation for one year can enhance bone mass in the hips of peripubertal girls." (said at 0:56:34)
A 1-year randomized, double-blind, placebo-controlled trial by Carpenter et al. (2006) evaluated the effect of dietary magnesium oxide supplementation (300 mg/day of elemental magnesium) in healthy 8- to 14-year-old girls with baseline low dietary magnesium intake. The study found a statistically significant increase in bone mineral content accrual at the hip in the magnesium-supplemented group compared to placebo.
A randomized controlled trial demonstrated that magnesium supplementation increased circulating 25-hydroxyvitamin D levels in individuals with low baseline vitamin D status.
"So this trial showed that for people with low 25-hydroxyvitamin D levels, which usually can indicate vitamin D deficiency, magnesium supplementation effectively increased these levels." (said at 1:00:34)
A double-blind randomized controlled trial (Dai et al., 2018; n = 180) nested within the Personalized Prevention of Colorectal Cancer Trial evaluated the effect of magnesium supplementation on vitamin D metabolites. The trial found that magnesium supplementation significantly increased plasma 25-hydroxyvitamin D3 [25(OH)D3] concentrations among individuals with lower baseline 25(OH)D levels (around 30 ng/mL or lower), whereas it decreased 25(OH)D3 when baseline levels were higher (~30 to 50 ng/mL), demonstrating a regulatory role of magnesium in optimizing vitamin D status.
Enzymes that transfer phosphate groups from phosphocreatine to ADP to produce ATP require magnesium as a cofactor.
"So creatine passes phosphate groups from phosphocreatine to ADP to make ATP, that energy currency. And so, you know, the enzymes that are doing this again require magnesium to do it." (said at 0:38:39)
Creatine kinase is the enzyme responsible for the reversible transfer of a phosphate group between phosphocreatine and ADP to regenerate ATP. Biochemical and structural crystallography studies confirm that creatine kinase requires magnesium (Mg2+) as an essential cofactor, acting via magnesium-nucleotide complexes ([Mg2+:ATP] and [Mg2+:ADP]) to facilitate phosphoryl transfer.
The reduction in mortality risk (especially from cardiovascular disease and colorectal cancer) associated with higher vitamin D levels is significantly greater in individuals with above-average magnesium intake.
"So this study found that the benefits of having higher vitamin D levels in reducing the risk of death, especially from cardiovascular disease and colorectal cancer, were more significant in individuals that had above-average intake of magnesium." (said at 0:59:46)
A cohort analysis of the US National Health and Nutrition Examination Survey (NHANES III) linked to the National Death Index evaluated the interaction between magnesium intake and serum 25-hydroxyvitamin D [25(OH)D] levels in relation to mortality. The study found that magnesium intake modified the association between serum 25(OH)D and mortality: inverse associations between vitamin D levels and risk of mortality—particularly from cardiovascular disease and colorectal cancer—were primarily present in individuals with magnesium intake above the median. Because this evidence comes from an observational cohort relying on dietary recall, the GRADE certainty is low.
Magnesium is required to convert vitamin D3 into 25-hydroxyvitamin D and to activate 25-hydroxyvitamin D into the active steroid hormone form.
"magnesium is aiding in the conversion of vitamin D3 into this more stable form of vitamin D, which is 25-hydroxyvitamin D. So what this tells us is that magnesium's influence on vitamin D status is not a one-size-fits-all; it really varies based on your existing vitamin D levels. It's playing a critical role in either helping stabilize vitamin D in the body, converting that vitamin D3 into that active that that stable circulating form, or it's also activating that circulating stabilized form, 25-hydroxyvitamin D, into the active steroid hormone" (said at 1:00:47)
Biochemical evidence and clinical trials confirm that magnesium acts as an essential cofactor for the enzymes involved in vitamin D synthesis, transport, and activation. In the liver, the conversion of vitamin D3 into circulating 25-hydroxyvitamin D [25(OH)D] by 25-hydroxylase requires magnesium, as does the subsequent renal conversion of 25(OH)D into the active steroid hormone form [1,25(OH)2D] by 1α-hydroxylase. Furthermore, randomized trial evidence demonstrates that the effect of magnesium supplementation on 25(OH)D levels interacts with baseline vitamin D concentrations, helping to optimize levels based on existing baseline status.
Approximately half of the US population does not consume sufficient magnesium.
"Well, if half the US population is not getting enough magnesium, and magnesium is required to make vitamin D function as an active steroid hormone, then you're going to have a problem." (said at 1:01:49)
Nationally representative dietary data from the National Health and Nutrition Examination Survey (NHANES) consistently demonstrate that roughly half of the United States population fails to meet the Estimated Average Requirement (EAR) for magnesium. For example, an analysis of NHANES 2007–2010 found that 46% of Americans aged 4 and older had total usual magnesium intake (including dietary supplements) below the EAR (and >50% from food alone). Long-term NHANES analyses (2003–2018) confirm that magnesium remains consistently underconsumed across the US population.
Hypertension affects nearly half of US adults, including 20% of young adults aged 18 to 39.
"So it affects nearly half of US adults, including 20% of young adults age 18 to 39, which wow, that's kind of important: 20% of young adults age 18 to 39 have hypertension." (said at 1:03:23)
Nationally representative surveillance data from the National Health and Nutrition Examination Survey (NHANES) support the claim. Under current clinical guidelines (systolic BP ≥130 mm Hg, diastolic BP ≥80 mm Hg, or taking antihypertensive medication), the prevalence of hypertension among all US adults was 47.7% (nearly half) in 2021–2023, and was 21.3% to 23.4% (approximately 1 in 5, or 20%) among young adults aged 18 to 39.
- supports: Hypertension Prevalence, Awareness, Treatment, and Control Among Adults Age 18 and Older: … (NCHS data brief 2024) · cited 25x in the literature
"During August 2021-August 2023, the prevalence of hypertension in adults was 47.7%, was higher in men (50.8%) than women (44.6%), and increased with age: 23.4% for ages 18-39, 52.5% for 40-59, and 71.6% for 60 and older." (abstract, results, passage verified)
pubmed - supports: Trends in Hypertension Prevalence, Awareness, Treatment, and Control Among US Young Adults… (American journal of hypertension 2025) · cited 22x in the literature
"In 2021-2023, 21.3% (20.4 million) young adults aged 18-39 years had stage 1 or 2 hypertension, of whom only 28.3% were aware of their condition and 5.6% achieved BP control to <130/80 mm Hg." (abstract, results, passage verified)
pubmedfull study (doi)
Cumulative exposure to elevated blood pressure from a young age significantly increases the risk of dementia later in life by causing damage to the small vessels of the brain.
"Elevated blood pressure is not only going to increase the risk of cardiovascular diseases, but it also significantly raises the risk of dementia later in life. And what's the most important factor for that is the cumulative exposure to high blood pressure. So the earlier in life you get high blood pressure, the more the risk you have of dementia later in life, and this is because sustained high blood pressure can lead to damage in the small vessels of the brain, and that impairs cognitive functions and potentially leads to conditions like dementia as a person ages." (said at 1:03:53)
Longitudinal cohort studies demonstrate that cumulative exposure to elevated blood pressure beginning in early adulthood and midlife is significantly associated with subsequent cognitive decline, structural brain changes, and markers of cerebral small vessel disease (such as increased white matter hyperintensity volume). Evidence from cohorts including the CARDIA study and the Insight 46 birth cohort shows that early adulthood systolic and diastolic blood pressure elevations and rate of increase predict higher white matter hyperintensity burden, smaller brain volumes, and lower cognitive test scores later in life.
- supports: Associations between blood pressure across adulthood and late-life brain structure and pat… (The Lancet. Neurology 2019) · cited 272x in the literature
"High and increasing blood pressure from early adulthood into midlife seems to be associated with increased WMHV and smaller brain volumes at 69-71 years of age." (abstract, conclusions, passage verified)
pubmedfull study (doi) - supports: Impact of Cardiovascular Risk Factors in Adolescence, Young Adulthood, and Midlife on Late… (The journals of gerontology. Series A, Biological sciences and medical sciences 2021) · cited 29x in the literature
"Adolescents with hypertension had lower late-life executive function compared to normotensive adolescents (β [95% CI]: -0.39 [-0.67, -0.11]). Young adulthood hypertension (β [95% CI]: -0.29 [-0.49, -0.09]) and midlife hyperlipidemia (β [95% CI]: -0.386 [-0.70, -0.02]) were associated with lower verbal episodic memory." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Effects and Thresholds of Young to Midlife Vascular Risks on Brain Health. (Hypertension (Dallas, Tex. : 1979) 2024) · cited 6x in the literature
"SBP in early adulthood is the vascular risk factor most strongly associated with midlife cognitive performance and white matter hyperintensity burden, with SBP 111 mm Hg suggested as a harm threshold." (abstract, conclusions, passage verified)
pubmedfull study (doi)
Magnesium lowers blood pressure by stimulating the production of prostacyclin and nitric oxide, which dilate blood vessels.
"Well, magnesium helps control blood pressure by boosting the production of substances like prostacyclin and nitric oxide, which relax blood vessels and improve overall cardiovascular health. It also aids in the widening of blood vessels, which reduces blood pressure, so vasodilation." (said at 1:04:27)
Magnesium contributes to vascular tone regulation and blood pressure control by acting as a natural calcium channel blocker and promoting the synthesis and release of vasodilator mediators, specifically nitric oxide and prostacyclin (prostaglandin I2). These actions promote vascular smooth muscle relaxation and vasodilation.
A meta-analysis of 34 randomized controlled trials with over 2,000 participants found that magnesium supplementation at an average dose of 368 mg/day significantly lowers both systolic and diastolic blood pressure.
"So there was a comprehensive meta-analysis involving 34 different randomized controlled trials, there was over 2,000 participants, and researchers discovered that magnesium supplementation at an average dose of 368 milligrams per day notably lowers both systolic and diastolic blood pressures." (said at 1:05:22)
A 2016 meta-analysis of 34 randomized, double-blind, placebo-controlled trials involving 2,028 participants found that oral magnesium supplementation at a median dose of 368 mg/day for a median duration of 3 months significantly lowered both systolic blood pressure (by 2.00 mm Hg, 95% CI: 0.43 to 3.58) and diastolic blood pressure (by 1.78 mm Hg, 95% CI: 0.73 to 2.82).
Evidence supporting magnesium supplementation for reducing muscle cramps is generally weak, though some studies suggest benefits in pregnant women.
"Some studies suggest benefits, especially in pregnant women, but the broader picture is a little more complex... I would say, overall, the data is not very strong supporting magnesium supplementation and its effects on reducing muscle cramps" (said at 1:07:27)
The speaker's claim accurately reflects the findings of high-quality systematic reviews. A Cochrane systematic review on magnesium for skeletal muscle cramps (PMID: 32956536) evaluated 11 randomized controlled trials (735 participants) and found that for idiopathic rest cramps (largely in older adults), magnesium provided no statistically significant or clinically meaningful reduction in cramp frequency, intensity, or duration compared to placebo (moderate- to high-certainty evidence). For pregnancy-associated leg cramps, a separate Cochrane review (PMID: 33275278) noted that while individual small trials have suggested potential benefits (such as reduced cramp frequency or pain intensity), overall findings across studies are conflicting, of low-to-very-low certainty, and at substantial risk of bias.
- supports: Magnesium for skeletal muscle cramps. (The Cochrane database of systematic reviews 2020)
"For idiopathic cramps, largely in older adults (mean age 61.6 to 69.3 years) presumed to have nocturnal leg cramps (the commonest presentation), differences in measures of cramp frequency when comparing magnesium to placebo were small, not statistically significant, and showed minimal heterogeneity (I² = 0% to 12%)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Interventions for leg cramps in pregnancy. (The Cochrane database of systematic reviews 2020)
"Oral magnesium versus placebo/no treatment The results for frequency of leg cramps were inconsistent. In one study, results indicated that women may be more likely to report never having any leg cramps after treatment (risk ratio (RR) 5.66, 95% confidence interval (CI) 1.35 to 23.68, 1 trial, 69 women, low-certainty evidence)... However, other findings indicated that magnesium may make little to no difference in the frequency of leg cramps during differing periods of treatment." (abstract, results, passage verified)
pubmedfull study (doi)
Dead Sea salt is high in magnesium and has been shown in studies to improve skin barrier function and hydration.
"There are I would say there have at least been some studies showing that Epsom salt, particularly Dead Sea salt so Dead Sea salt is high in magnesium it can improve skin barrier function and and hydration as well." (said at 1:10:31)
Clinical evidence supports the claim. A controlled trial in volunteers with atopic dry skin evaluated bathing in a magnesium-rich Dead Sea salt solution (5%) compared to tap water control. The study found that bathing in the Dead Sea salt solution significantly improved skin barrier function (reduced transepidermal water loss) and enhanced stratum corneum hydration, effects attributed to its high magnesium content.
There is no scientific evidence demonstrating that soaking in Epsom salt increases plasma magnesium levels or improves muscle cramps.
"not to mention that there's never been any indication that Epsom salt soaking in Epsom salt can actually increase any plasma magnesium levels. Like, that's I have not seen that study showing that... But with respect to muscle cramping, you know, I would say that there's no real scientific validation that Epsom salts are going to improve muscle cramps." (said at 1:10:01)
Scientific reviews and experimental studies confirm that transdermal absorption of magnesium from Epsom salt (magnesium sulfate) baths across intact human skin is scientifically unsupported. Intact stratum corneum forms an effective barrier against magnesium ion penetration, resulting in no reliable evidence that soaking in Epsom salt increases systemic or plasma magnesium levels. Furthermore, systematic reviews of magnesium for skeletal muscle cramps (including the Cochrane systematic review) have found no evidence supporting the efficacy of transdermal magnesium salts for alleviating or preventing muscle cramps.
The DASH diet, which includes foods rich in magnesium, has been shown in studies to help manage hypertension.
"there's been a lot of studies out there showing things like a DASH diet, which are which include a lot of foods that are rich in magnesium, is another great way to manage hypertension or high blood pressure as well." (said at 1:06:27)
Extensive evidence from randomized controlled feeding trials and systematic reviews demonstrates that the Dietary Approaches to Stop Hypertension (DASH) diet significantly reduces blood pressure in individuals with prehypertension and hypertension. The DASH dietary pattern is characterized by high intakes of fruits, vegetables, whole grains, and nuts, which provide substantial amounts of dietary magnesium, potassium, calcium, and fiber.
- supports: Descriptive characteristics of the dietary patterns used in the Dietary Approaches to Stop… (Journal of the American Dietetic Association 1999) · cited 277x in the literature
"The fruits and vegetables and combination diets contained relatively more servings of fruits, juices, vegetables, and nuts/seeds, and were higher in magnesium, potassium, and fiber than was the control diet." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Dietary Approaches to Stop Hypertension (DASH) for the primary and secondary prevention of… (The Cochrane database of systematic reviews 2025) · cited 10x in the literature
"The Dietary Approaches to Stop Hypertension (DASH) diet is designed to lower blood pressure and improve cardiovascular health by reducing sodium and unhealthy fats while increasing nutrients, including potassium, calcium, magnesium, and fibre." (abstract, background, passage verified)
pubmedfull study (doi)
Studies suggest that topical magnesium can penetrate the skin through sweat glands and hair follicles.
"there are some studies that suggest a pathway for magnesium penetration via the sweat glands and hair follicles, representing a very small fraction of the skin's overall surface area." (said at 1:09:50)
Published experimental research demonstrates that topically applied magnesium ions can permeate human skin via hair follicles. An in vitro study evaluating human skin permeation found that topical magnesium penetration is concentration- and time-dependent, and that follicular pathways significantly contribute to this penetration.
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.